Rates of hospitalization after ICI treatment across cancer type, ICI, and AID*
| Hospitalization | ||
| AID | No AID | |
| Melanoma PD-1 inhibitors | 24.1%*** (13/54) (RR=4.2) | 5.8% (28/480) |
| Lung cancer PD-1 inhibitors | 38.2% (52/136) (RR=1.2) | 32.5% (556/1711) |
| All cancers PD-1 inhibitors | 34.2%* (65/190) (RR=1.3) | 26.1% (572/2191) |
| Melanoma ipilimumab | 10.6% (10/94) (RR=1.5) | 6.9% (72/1039) |
| Melanoma ipilimumab-nivolumab combo | 42.9%* (3/7) (RR=4.4) | 9.8% (4/41) |
*Values with * were significantly different at p<0.05 when comparing AID versus non-AID patients within particular subgroups, values with *** were significant at p<0.001.
AID, autoimmune disease; ICI, immune checkpoint inhibitor.